B

조아제약

034940KOSDAQ

61.1 / 100

Reference Date: 2026-09-08

Financial Score17.0 / 40
News Sentiment19.1 / 25
Momentum15.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 428.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Joa Pharmaceutical, established in 1988, primarily engages in the production and sale of general pharmaceuticals, health functional foods, and is developing pet pharmaceuticals and nutritional supplements. It operates a nationwide pharmacy franchise, Medipham, and supplies over 200 products, including liver disease treatment drug Hepatos, memory improvement drug Joa Baiton, and children's health beverage Jalketon. The company has been exporting its products to 23 countries, including Vietnam, China, and the U.S., since 1995.

Number of Employees

243people

Average Salary

62.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
0.83Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-29.26Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
32.88Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼2.9% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼4.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -28.1% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 1Negative 0Average Sentiment Score 76.2

Detailed Momentum

52-week position8.0Point

Near 52w high (88%, uptrend)

Current 2,905Won52-week high 3,23052-week low 505
1-month return6.0Point

1m +428.18% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-08-26
  • Neutral반기보고서 (2026.06)2026-08-14